X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to co-develop VRG50635, Verge’s potent, orally bioavailable PIKfyve inhibitor, for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS), in Europe, Central and South America, Southeast Asia and Japan.
Lead Product(s): VRG50635
Therapeutic Area: Neurology Product Name: VRG50635
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Verge Genomics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 25, 2024
Details:
Under the licensing agreement, Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90, an O-GlcNAcase inhibitor, in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.
Lead Product(s): ASN90
Therapeutic Area: Neurology Product Name: ASN90
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Asceneuron
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 22, 2023
Details:
The polypill includes three drugs (aspirin, an ACE inhibitor, and a statin), is effective at preventing secondary adverse cardiovascular events in people who have previously had a heart attack.
Lead Product(s): Aspirin,Ramipril,Simvastatin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Polypill
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CNIC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2022
Details:
Under the agreement, Ferrer has been appointed as the exclusive, worldwide distributor to commercialise Tyvaso (treprostinil) for the treatment of PH-ILD, a rare, serious and progressive disease without an approved treatment in Europe and many other parts of the world.
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Tyvaso
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: United Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 28, 2022
Details:
FNP122 as an oral formulation of edaravone in ALS patients. Edaravone is an antioxidant and free radical scavenger that has been shown to reduce excess oxidative stress and cell death1, playing an important role in the pathology of ALS.
Lead Product(s): Edaravone
Therapeutic Area: Neurology Product Name: FNP122
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Details:
FNP122 is an oral formulation of edaravone, a compound that prevents oxidative stress on a cellular level. Therefore, reducing oxidative stress can delay the progression of ALS.
Lead Product(s): Edaravone
Therapeutic Area: Neurology Product Name: FNP122
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Treeway
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 20, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
